Cytiva, a biopharma research and manufacturing specialist, rolled out a new cell therapy manufacturing platform the company developed as part of a collaboration with Gilead Sciences’ Kite Pharma unit.

The MarketWatch News Department was not involved in the creation of this content. -- Collaboration combines Nuclera's eProtein Discovery System, which accelerates protein expression, purification and ...

Biopharma’s ongoing quest to develop COVID-19 drugs and vaccines, plus growing industry demand for producing various types of new therapies, are fueling the $1.5-billion expansion of manufacturing ...

Cytiva, a Massachusetts-based research and biopharma manufacturing specialist, has opened the doors to its production facility in Cardiff, Wales. The 11,000-square-meter Welsh facility is already ...

AMERSHAM, United Kingdom, Feb. 1, 2021 /PRNewswire/ -- Cytiva has acquired Vanrx Pharmasystems, a Canadian company that makes robotic aseptic filling machines to fill vials, syringes, and cartridges ...

Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, is collaborating with Cytiva, a global life sciences leader, to provide customers with an integrated ...

Cytiva’s acquisition of CEVEC Pharmaceuticals strengthens the company’s cell line development and biomanufacturing capabilities. Cytiva has acquired CEVEC Pharmaceuticals, a Germany-based provider of ...

Cytiva and Bayer signed a multi-year development agreement to jointly develop the first modular end-to-end manufacturing platform for allogeneic cell therapies. According to Jens Vogel, PhD, senior ...

Cytiva announced in a Feb. 1, 2021 press release that it had acquired Vanrx Pharmasystems, a Canadian company that makes robotic aseptic filling machines. It is Cytiva’s first acquisition since ...

Collaboration combines Nuclera’s eProtein Discovery System, which accelerates protein expression, purification and optimization, with Cytiva’s Biacore SPR system, which characterizes molecular ...

Cambridge, UK and Marlborough, MA, 28 May 2025: Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ System, has announced a ...